Compare DAIO & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | MIRA |
|---|---|---|
| Founded | 1969 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 43.7M |
| IPO Year | 1995 | 2023 |
| Metric | DAIO | MIRA |
|---|---|---|
| Price | $3.91 | $0.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.22 | N/A |
| AVG Volume (30 Days) | 64.5K | ★ 84.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,500,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.16 | $0.90 |
| 52 Week High | $4.49 | $2.45 |
| Indicator | DAIO | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 46.20 |
| Support Level | $2.98 | $0.92 |
| Resistance Level | $4.10 | $1.22 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 52.94 | 41.94 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.